Meeting
2019 Genitourinary Cancers Symposium
Exploratory endpoints in a FARETES study of the efficacy of testosterone in metastatic renal cell carcinoma (mRCC) patients.
Authors
Ilya Tsimafeyeu
Kidney Cancer Research Bureau, Moscow, Russian Federation
Ilya Tsimafeyeu , Pavel Borisov , Ruslan Zukov , Kristina Zakurdaeva , Anastasia Bondarenko , Yulia Tishova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03379012
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 574)
DOI
10.1200/JCO.2019.37.7_suppl.574
Abstract #
574
Poster Bd #
E13
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A FARETES study of the efficacy and safety of testosterone in metastatic renal cell carcinoma patients with fatigue.
First Author: Ilya Tsimafeyeu
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst
Poster
2015 Genitourinary Cancers Symposium
Outcomes of patients with late relapse metastatic renal cell carcinoma treated with targeted therapies: A single-institution experience.
First Author: Kamal Kishore Mandalapu
Poster
2012 ASCO Annual Meeting
Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience.
First Author: Marc Ryan Matrana